Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 12/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 3/20 | 0.31 |
| ▸ | PRKCI | P41743 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409699 | 1.00 | P2RY12 (0.51) | P2RY12TRPV1TMIGD3ADORA1IDH2 | |
| SCHEMBL13460011 | 0.94 | P2RY12 (0.43) | P2RY12TRPV1TMIGD3ADORA1PRKCI | |
| SCHEMBL1966501 | 0.83 | TMIGD3 (0.37) | P2RY12TRPV1TMIGD3ADORA1 | |
| SCHEMBL1967591 | 0.78 | P2RY12 (0.43) | P2RY12TRPV1TMIGD3ADORA1 | |
| SCHEMBL1966749 | 0.73 | P2RY12 (0.43) | P2RY12 | |
| SCHEMBL1968302 | 0.72 | P2RY12 (0.56) | P2RY12TMIGD3 | |
| SCHEMBL12409400 | 0.72 | P2RY12 (0.56) | P2RY12TMIGD3 | |
| SCHEMBL1968135 | 0.72 | P2RY12 (0.39) | P2RY12 | |
| SCHEMBL1970916 | 0.72 | HTR6 (0.40) | P2RY12TRPV1 | |
| SCHEMBL12409664 | 0.72 | HTR6 (0.40) | P2RY12TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2011-07-07 | — | — | US | disclosed |
| EP-2334689-A2 | FUSED HETEROCYCLIC COMPOUND | LG Life Sciences Ltd. (KR) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010027236-A2 | FUSED HETEROCYCLIC COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166121-A1 | FUSED HETEROCYCLIC COMPOUND | F2, PF4, F11 | P2RY12 127/4885TRPV1 2200/4885TMIGD3 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.